Brandenburg Kapital - News about Adrenomed AG
Adrenomed closes EUR 22 million equity financing - The money will be used to further develop the product candidate Adrecizumab
Potsdam/Hennigsdorf - Dezember 2020. Adrenomed AG, a pharmaceutical company focused on restoring the vascular integrity of blood vessels, announced the successful closing of a EUR 22.2 million Series E financing round.
With the participation of the existing investors Wellington Partners and HBM Healthcare Investments as well as Brandenburg Kapital and other investors, the financing round was completed. This will provide the company with funds to further develop the product candidate Adrecizumab in septic shock, an area with very high unmet medical needs.
Please read more information about Adrenomed AG below in the download section.
About Adrenomed
Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate Adrecizumab is a first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock.
For further information, please visit www.adrenomed.com and www.brandenburg-kapital.de